Skip to main content
Julie Brahmer, MD, Oncology, Baltimore, MD, Johns Hopkins Hospital


Oncology Baltimore, MD

Thoracic Cancer

Professor of Oncology, Johns Hopkins University School of Medicine; Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus), Co-Director, Upper Aerodigestive Program

Dr. Brahmer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Brahmer's full profile

Already have an account?


  • Dr. Julie Brahmer is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including Johns Hopkins Hospital and Johns Hopkins Bayview Medical Center. She received her medical degree from University of Nebraska College of Medicine and has been in practice 24 years. She specializes in thoracic oncology and is experienced in gastrointestinal oncology, and general medical oncology.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
  • University of Utah Health
    University of Utah HealthResidency, Internal Medicine, 1993 - 1997
  • University of Nebraska College of Medicine
    University of Nebraska College of MedicineClass of 1993

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • DC State Medical License
    DC State Medical License 2022 - 2024
  • MD State Medical License
    MD State Medical License 1997 - 2024
  • UT State Medical License
    UT State Medical License 1994 - 1998
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • Fellow (FASCO) American Society of Clinical Oncologists, 2011

Clinical Trials

Publications & Presentations


Journal Articles

  • Immune-Related (IR)-Pneumonitis During the COVID-19 Pandemic: Multidisciplinary Recommendations for Diagnosis and Management  
    Joshua E Reuss, Karthik Suresh, David Feller-Kopman, Clare Rock, Julie R Brahmer, Journal For Immunotherapy of Cancer


  • Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies. 
    2019 ASCO Annual Meeting - 6/1/2019
  • General Management of Immune-Related Toxicities Incorporating Guidelines Into Practice 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
  • Emerging Strategies in Treatment of Non−Small-Cell Lung Cancer and Head & Neck Cancer 2012 
    CancerNet, LLC, Atlanta, Georgia - 6/16/2012

Authored Content

  • Evaluation of Health-Related Quality of Life and Symptoms in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer Treated with Nivolumab or Docetaxel in CheckMate 057September 2018

Press Mentions

  • Brahmer Highlights Five-Year Nivolumab Findings in NSCLC
    Brahmer Highlights Five-Year Nivolumab Findings in NSCLCApril 18th, 2017
  • OncLive® Presents the Latest State of the Science Summit™ on Advances in Lung Cancer Management
    OncLive® Presents the Latest State of the Science Summit™ on Advances in Lung Cancer ManagementOctober 29th, 2018
  • Immunotherapy Drug Improves Survival for Common Form of Lung Cancer
    Immunotherapy Drug Improves Survival for Common Form of Lung CancerMay 31st, 2015
  • Join now to see all


  • Member, Update Committee of the ASCO NSCLC Expert Panel, American Society of Clinical Oncology 2015 - Present

Professional Memberships

Hospital Affiliations